HC Wainwright Estimates MindWalk FY2031 Earnings

MindWalk Holdings Corp. (NASDAQ:HYFT) – Equities research analysts at HC Wainwright issued their FY2031 EPS estimates for MindWalk in a research report issued on Thursday, July 23rd. HC Wainwright analyst S. Ramakanth expects that the company will earn $0.13 per share for the year. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for MindWalk’s current full-year earnings is ($0.17) per share.

MindWalk (NASDAQ:HYFT) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). MindWalk had a negative net margin of 89.65% and a negative return on equity of 92.61%. The company had revenue of $3.03 million during the quarter.

Several other equities research analysts have also recently commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of MindWalk in a research note on Wednesday, July 15th. Wall Street Zen cut shares of MindWalk from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, JonesTrading started coverage on shares of MindWalk in a research note on Thursday, April 16th. They set a “buy” rating and a $5.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, MindWalk presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.00.

MindWalk Stock Performance

NASDAQ:HYFT opened at $1.36 on Friday. The stock’s fifty day moving average price is $1.56. MindWalk has a 52-week low of $0.99 and a 52-week high of $3.25. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.64 and a current ratio of 2.80. The firm has a market cap of $63.53 million, a P/E ratio of -6.18 and a beta of 0.83.

Institutional Investors Weigh In On MindWalk

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC boosted its holdings in MindWalk by 147.3% during the fourth quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock worth $293,000 after buying an additional 96,018 shares during the last quarter. Bridgeway Capital Management LLC acquired a new position in shares of MindWalk during the 4th quarter worth about $91,000. XTX Topco Ltd increased its stake in shares of MindWalk by 118.6% in the 4th quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock valued at $149,000 after acquiring an additional 44,331 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of MindWalk in the 4th quarter valued at approximately $51,000. Finally, Bank of Montreal Can boosted its stake in MindWalk by 81.0% during the 4th quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock worth $100,000 after acquiring an additional 24,500 shares during the last quarter. Institutional investors own 6.70% of the company’s stock.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.